[go: up one dir, main page]

DE60332277D1 - Verabreichung von sirnas - Google Patents

Verabreichung von sirnas

Info

Publication number
DE60332277D1
DE60332277D1 DE60332277T DE60332277T DE60332277D1 DE 60332277 D1 DE60332277 D1 DE 60332277D1 DE 60332277 T DE60332277 T DE 60332277T DE 60332277 T DE60332277 T DE 60332277T DE 60332277 D1 DE60332277 D1 DE 60332277D1
Authority
DE
Germany
Prior art keywords
sirnas
administration
delivery
delivery methods
dendrimers
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60332277T
Other languages
English (en)
Inventor
Tariq M Rana
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Massachusetts Amherst
Original Assignee
University of Massachusetts Amherst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Massachusetts Amherst filed Critical University of Massachusetts Amherst
Application granted granted Critical
Publication of DE60332277D1 publication Critical patent/DE60332277D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/111—General methods applicable to biologically active non-coding nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
    • C12Y207/11—Protein-serine/threonine kinases (2.7.11)
    • C12Y207/11022—Cyclin-dependent kinase (2.7.11.22)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C12N2310/3513—Protein; Peptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/32—Special delivery means, e.g. tissue-specific

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Virology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
DE60332277T 2002-11-26 2003-11-24 Verabreichung von sirnas Expired - Lifetime DE60332277D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US43052002P 2002-11-26 2002-11-26
PCT/US2003/037886 WO2004048545A2 (en) 2002-11-26 2003-11-24 DELIVERY OF siRNAs______________________________________________

Publications (1)

Publication Number Publication Date
DE60332277D1 true DE60332277D1 (de) 2010-06-02

Family

ID=32393595

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60332277T Expired - Lifetime DE60332277D1 (de) 2002-11-26 2003-11-24 Verabreichung von sirnas

Country Status (8)

Country Link
US (2) US20040204377A1 (de)
EP (1) EP1585756B1 (de)
AT (1) ATE465255T1 (de)
AU (1) AU2003298724B2 (de)
CA (1) CA2506714A1 (de)
DE (1) DE60332277D1 (de)
ES (1) ES2343318T3 (de)
WO (1) WO2004048545A2 (de)

Families Citing this family (131)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080281041A1 (en) * 1999-06-07 2008-11-13 Rozema David B Reversibly Masked Polymers
US8137695B2 (en) * 2006-08-18 2012-03-20 Arrowhead Madison Inc. Polyconjugates for in vivo delivery of polynucleotides
US8541548B2 (en) * 1999-06-07 2013-09-24 Arrowhead Madison Inc. Compounds and methods for reversible modification of biologically active molecules
US6692700B2 (en) 2001-02-14 2004-02-17 Handylab, Inc. Heat-reduction methods and systems related to microfluidic devices
US7829025B2 (en) 2001-03-28 2010-11-09 Venture Lending & Leasing Iv, Inc. Systems and methods for thermal actuation of microfluidic devices
US8895311B1 (en) 2001-03-28 2014-11-25 Handylab, Inc. Methods and systems for control of general purpose microfluidic devices
US7010391B2 (en) 2001-03-28 2006-03-07 Handylab, Inc. Methods and systems for control of microfluidic devices
KR100468316B1 (ko) 2002-01-29 2005-01-27 주식회사 웰진 Ｄｎａ의 세포 또는 조직 내 전달 효율을 높이는 펩타이드
US8008355B2 (en) * 2002-03-11 2011-08-30 Roche Madison Inc. Endosomolytic poly(vinyl ether) polymers
US8138383B2 (en) * 2002-03-11 2012-03-20 Arrowhead Madison Inc. Membrane active heteropolymers
US20040147027A1 (en) * 2003-01-28 2004-07-29 Troy Carol M. Complex for facilitating delivery of dsRNA into a cell and uses thereof
EP2407243B1 (de) 2003-07-31 2020-04-22 Handylab, Inc. Mehrschichtige mikrofluidische vorrichtung
EP1704228B1 (de) * 2004-01-16 2012-04-11 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Immunokinasen
WO2005079533A2 (en) * 2004-02-17 2005-09-01 University Of Massachusetts Methods and compositions for mediating gene silencing
WO2005084412A2 (en) * 2004-03-05 2005-09-15 Archemix Corp. Controlled modulation of the pharmacokinetics and biodistribution of aptamer therapeutics
EP1773998A2 (de) * 2004-04-20 2007-04-18 Nastech Pharmaceutical Company Inc. Verfahren und zusammensetzungen zur verstärkten abgabe von doppelstrang-rna oder einer doppelstrangigen hybrid-nukleinsäure zur regulierung der genexpression in säugerzellen
US8852862B2 (en) 2004-05-03 2014-10-07 Handylab, Inc. Method for processing polynucleotide-containing samples
MXPA06012605A (es) * 2004-05-04 2006-12-15 Nastech Pharm Co Composiciones y metodos para mejorar el suministro de acidos nucleicos en celulas y para modificar la expresion de genes objetivo en celulas.
US20060035815A1 (en) * 2004-05-04 2006-02-16 Nastech Pharmaceutical Company Inc. Pharmaceutical compositions for delivery of ribonucleic acid to a cell
US20060040882A1 (en) * 2004-05-04 2006-02-23 Lishan Chen Compostions and methods for enhancing delivery of nucleic acids into cells and for modifying expression of target genes in cells
US20050260214A1 (en) * 2004-05-12 2005-11-24 Simon Michael R Composition and method for introduction of RNA interference sequences into targeted cells and tissues
US20060030003A1 (en) * 2004-05-12 2006-02-09 Simon Michael R Composition and method for introduction of RNA interference sequences into targeted cells and tissues
US20050255120A1 (en) * 2004-05-12 2005-11-17 Simon Michael R Composition and method for introduction of DNA directed RNA interference sequences into targeted cells and tissues
EP1789447B1 (de) * 2004-08-16 2012-04-25 Immune Disease Institute, Inc. Verfahren zur lieferung von rna-interferenz und verwendungen damit
US9315862B2 (en) * 2004-10-05 2016-04-19 California Institute Of Technology Aptamer regulated nucleic acids and uses thereof
ATE505540T1 (de) * 2004-11-16 2011-04-15 Qiagen Gmbh Genabschaltung (gene silencing) durch hybride sens-dna und antisens-rna konstrukte, gekoppelt an ein peptid zur erleichterten aufnahme in zellen
JP2008527993A (ja) * 2005-01-24 2008-07-31 アヴァリス・アクチエボラーグ 特異性及び送達の改善のためのｓｉＲＮＡ分子、ｓｈＲＮＡ分子又はアンチセンス分子及び機能的実体を含む複合体
AU2006208084B2 (en) 2005-01-25 2012-07-26 Prolexys Pharmaceuticals, Inc. Quinoxaline Derivatives as Antitumor Agents
US8895717B2 (en) * 2005-04-15 2014-11-25 The Board Of Regents Of The University Of Texas System Delivery of siRNA by neutral lipid compositions
US20070106233A1 (en) * 2005-10-20 2007-05-10 Percutaneous Systems, Inc. Systems and methods for dilating and accessing body lumens
JP2009514877A (ja) * 2005-11-04 2009-04-09 エムディーアールエヌエー，インコーポレイテッド ｓｉＲＮＡの送達媒体としてのペプチド−ダイザ基質ＲＮＡ抱合体
ES2435420T3 (es) * 2005-12-15 2013-12-19 Centre National De La Recherche Scientifique - Cnrs Oligonucleótidos catiónicos, procedimientos automáticos para preparar los mismos y sus usos
EP1797901A1 (de) 2005-12-16 2007-06-20 Diatos Zelldurchlässige Peptidkonjugate zum Transfer von Nukleinsäuren in Zellen
EP1800695A1 (de) 2005-12-21 2007-06-27 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Immuno-RNA Konjugate
US20070212337A1 (en) * 2006-02-01 2007-09-13 The Johns Hopkins University Polypeptide-nucleic acid conjugate for immunoprophylaxis or immunotherapy for neoplastic or infectious disorders
EP1984399A4 (de) * 2006-02-10 2010-03-03 Univ California Transduzierbare abgabe von sirana mittels dsrna-bindedomänenfusionen an ptd/cpps
US10900066B2 (en) 2006-03-24 2021-01-26 Handylab, Inc. Microfluidic system for amplifying and detecting polynucleotides in parallel
ES2692380T3 (es) 2006-03-24 2018-12-03 Handylab, Inc. Método para realizar PCR con un cartucho con varias pistas
US11806718B2 (en) 2006-03-24 2023-11-07 Handylab, Inc. Fluorescence detector for microfluidic diagnostic system
US7998708B2 (en) 2006-03-24 2011-08-16 Handylab, Inc. Microfluidic system for amplifying and detecting polynucleotides in parallel
US20070269892A1 (en) * 2006-05-18 2007-11-22 Nastech Pharmaceutical Company Inc. FORMULATIONS FOR INTRACELLULAR DELIVERY dsRNA
US20070275923A1 (en) * 2006-05-25 2007-11-29 Nastech Pharmaceutical Company Inc. CATIONIC PEPTIDES FOR siRNA INTRACELLULAR DELIVERY
GB0613753D0 (en) * 2006-07-11 2006-08-23 Norwegian Radium Hospital Res Method
AU2007272906B2 (en) * 2006-07-12 2013-01-31 The Regents Of The University Of California Transducible delivery of nucleic acids by reversible phosphotriester charge neutralization protecting groups
US9127293B2 (en) * 2006-07-26 2015-09-08 The University Of Chicago Receptor-mediated delivery: compositions and methods
US20080076701A1 (en) * 2006-08-18 2008-03-27 Nastech Pharmaceutical Company Inc. Dicer substrate rna peptide conjugates and methods for rna therapeutics
US8017109B2 (en) * 2006-08-18 2011-09-13 Roche Madison Inc. Endosomolytic poly(acrylate) polymers
ES2484142T3 (es) 2006-09-06 2014-08-11 The Regents Of The University Of California Diagnóstico molecular y clasificación del melanoma maligno
US8158595B2 (en) * 2006-11-09 2012-04-17 California Institute Of Technology Modular aptamer-regulated ribozymes
WO2008060604A2 (en) 2006-11-14 2008-05-22 Handylab, Inc. Microfluidic system for amplifying and detecting polynucleotides in parallel
US8765076B2 (en) 2006-11-14 2014-07-01 Handylab, Inc. Microfluidic valve and method of making same
CN101011577B (zh) * 2007-02-12 2010-05-19 中国人民解放军第二军医大学 载生存素小分子rna聚酰胺树枝状聚合物纳米微粒
WO2008109432A2 (en) * 2007-03-02 2008-09-12 The Board Of Regents Of The University Of Texas System Therapeutic targeting of interleukins using sirna in neutral liposomes
US8678686B2 (en) * 2007-05-01 2014-03-25 Pgr-Solutions Multi-chain lipophilic polyamines
CN101674853B (zh) * 2007-05-04 2013-03-27 玛瑞纳生物技术有限公司 氨基酸脂质及其用途
US8182763B2 (en) 2007-07-13 2012-05-22 Handylab, Inc. Rack for sample tubes and reagent holders
US8287820B2 (en) 2007-07-13 2012-10-16 Handylab, Inc. Automated pipetting apparatus having a combined liquid pump and pipette head system
WO2009012185A1 (en) 2007-07-13 2009-01-22 Handylab, Inc. Polynucleotide capture materials, and methods of using same
US9186677B2 (en) 2007-07-13 2015-11-17 Handylab, Inc. Integrated apparatus for performing nucleic acid extraction and diagnostic testing on multiple biological samples
US8133671B2 (en) 2007-07-13 2012-03-13 Handylab, Inc. Integrated apparatus for performing nucleic acid extraction and diagnostic testing on multiple biological samples
US8105783B2 (en) 2007-07-13 2012-01-31 Handylab, Inc. Microfluidic cartridge
US9618139B2 (en) 2007-07-13 2017-04-11 Handylab, Inc. Integrated heater and magnetic separator
WO2009011855A2 (en) * 2007-07-16 2009-01-22 California Institute Of Technology Selection of nucleic acid-based sensor domains within nucleic acid switch platform
EP2587263A1 (de) * 2007-07-25 2013-05-01 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Selbstverknüpfende rekombinante Antikörper-Fusionsproteine
JP2010535248A (ja) * 2007-07-31 2010-11-18 ザ ジョンズ ホプキンス ユニバーシティー 腫瘍性障害または感染症の免疫学的予防または免疫療法のためのポリペプチド−核酸複合体
EP2522753B1 (de) 2007-08-13 2014-04-02 Baxter International Inc. IVIg-Modulation von Chemokinen zur Behandlung von Multipler Sklerose, Morbus Alzheimer und Morbus Parkinson
US8367815B2 (en) * 2007-08-28 2013-02-05 California Institute Of Technology Modular polynucleotides for ligand-controlled regulatory systems
US20120165387A1 (en) 2007-08-28 2012-06-28 Smolke Christina D General composition framework for ligand-controlled RNA regulatory systems
US8865667B2 (en) 2007-09-12 2014-10-21 California Institute Of Technology Higher-order cellular information processing devices
US8609347B2 (en) 2007-10-22 2013-12-17 The Regents Of The University Of California Biomarkers for prenatal diagnosis of congenital cytomegalovirus
WO2009062084A2 (en) * 2007-11-07 2009-05-14 University Of Utah Research Foundation Cleavable modifications to reducible poly(amido ethylenimine)s to enhance nucleotide delivery
US9029524B2 (en) * 2007-12-10 2015-05-12 California Institute Of Technology Signal activated RNA interference
FR2926818B1 (fr) * 2008-01-30 2012-04-06 Centre Nat Rech Scient siRNA CATIONIQUES, SYNTHESE ET UTILISATION POUR L'ARN INTERFERENCE
AU2009213147A1 (en) 2008-02-11 2009-08-20 Rxi Pharmaceuticals Corp. Modified RNAi polynucleotides and uses thereof
EP2257810B1 (de) 2008-03-05 2013-06-05 The Regents of the University of California Molekulare diagnose und klassifikation bösartiger melanome
USD787087S1 (en) 2008-07-14 2017-05-16 Handylab, Inc. Housing
US8815818B2 (en) 2008-07-18 2014-08-26 Rxi Pharmaceuticals Corporation Phagocytic cell delivery of RNAI
CN102405286A (zh) 2008-09-22 2012-04-04 阿克赛医药公司 减小大小的自递送RNAi化合物
EP3495488A1 (de) 2008-10-27 2019-06-12 Baxalta GmbH Modelle von thrombotischer thrombozytopenischer purpura und verfahren zur verwendung davon
WO2010059226A2 (en) 2008-11-19 2010-05-27 Rxi Pharmaceuticals Corporation Inhibition of map4k4 through rnai
WO2010078536A1 (en) 2009-01-05 2010-07-08 Rxi Pharmaceuticals Corporation Inhibition of pcsk9 through rnai
WO2010090762A1 (en) 2009-02-04 2010-08-12 Rxi Pharmaceuticals Corporation Rna duplexes with single stranded phosphorothioate nucleotide regions for additional functionality
US8329882B2 (en) 2009-02-18 2012-12-11 California Institute Of Technology Genetic control of mammalian cells with synthetic RNA regulatory systems
US9145555B2 (en) 2009-04-02 2015-09-29 California Institute Of Technology Integrated—ligand-responsive microRNAs
WO2010129853A2 (en) 2009-05-07 2010-11-11 The Regents Of The University Of California TRANSDUCIBLE DELIVERY OF NUCLEIC ACIDS USING MODIFIED dsRNA BINDING DOMAINS
CA2780741C (en) 2009-10-12 2023-04-04 Smith Holdings, Llc Methods and compositions for modulating gene expression using oligonucleotide based drugs administered in vivo or in vitro
EP2513309A2 (de) 2009-12-18 2012-10-24 Novartis AG Organische zusammensetzungen zur behandlung von hsf1-bedingten erkrankungen
US20130137584A1 (en) 2010-02-01 2013-05-30 The Regents Of The University Of California Novel diagnostic and therapeutic targets associated with or regulated by n-cadherin expression and/or epithelial to mesenchymal transition (emt) in prostate cancer and other malignancies
JP2013519869A (ja) 2010-02-10 2013-05-30 ノバルティス アーゲー 筋肉成長のための方法および化合物
CN102869774B (zh) 2010-02-24 2018-02-09 箭头研究公司 用于靶向递送siRNA的组合物
RU2615143C2 (ru) 2010-03-24 2017-04-04 Адвирна Самодоставляющие PHKi соединения уменьшенного размера
CN103200945B (zh) 2010-03-24 2016-07-06 雷克西制药公司 眼部症候中的rna干扰
KR20180044433A (ko) 2010-03-24 2018-05-02 알엑스아이 파마슈티칼스 코포레이션 진피 및 섬유증성 적응증에서의 ｒｎａ 간섭
JP2013523149A (ja) 2010-04-09 2013-06-17 メルク・シャープ・エンド・ドーム・コーポレイション 新規な単一化学物質およびオリゴヌクレオチドの送達方法
AR081082A1 (es) 2010-04-23 2012-06-06 Novartis Ag Composiciones organicas para tratar enfermedades relacionadas con beta-enac
JP2013541951A (ja) 2010-10-01 2013-11-21 アメリカ合衆国 ｐ５３アイソフォームによる幹細胞機能の操作
CN106190806B (zh) 2011-04-15 2018-11-06 贝克顿·迪金森公司 扫描实时微流体热循环仪和用于同步的热循环和扫描光学检测的方法
BR112014005103A2 (pt) 2011-09-02 2017-07-04 Novartis Ag composições orgânicas para tratar doenças associadas com hsf1
EP2758036A2 (de) * 2011-09-21 2014-07-30 Yissum Research and Development Company of The Hebrew University of Jerusalem Nanoausgabesysteme
EP3273253B1 (de) 2011-09-30 2020-08-26 Becton, Dickinson and Company Vereinheitlichter reagenzienstreifen
USD692162S1 (en) 2011-09-30 2013-10-22 Becton, Dickinson And Company Single piece reagent holder
CN104040238B (zh) 2011-11-04 2017-06-27 汉迪拉布公司 多核苷酸样品制备装置
CA2860676A1 (en) 2012-01-09 2013-07-18 Novartis Ag Organic compositions to treat beta-catenin-related diseases
BR112014018995B1 (pt) 2012-02-03 2021-01-19 Becton, Dickson And Company sistemas para executar ensaio automatizado
US20150238515A1 (en) 2012-05-02 2015-08-27 Arrowhead Research Corporation Organic compositions to treat kras-related diseases
IN2015DN01765A (de) 2012-08-20 2015-05-29 Univ California
US9801953B2 (en) 2012-10-15 2017-10-31 Emory University Nanoparticles carrying nucleic acid cassettes for expressing RNA
WO2014134255A2 (en) 2013-02-28 2014-09-04 Novartis Ag Organic compositions to treat epas1-related diseases
WO2015051135A2 (en) 2013-10-04 2015-04-09 Novartis Ag Organic compositions to treat hepcidin-related diseases
WO2015069586A2 (en) * 2013-11-06 2015-05-14 Merck Sharp & Dohme Corp. Dual molecular delivery of oligonucleotides and peptide containing conjugates
EP3169784B1 (de) 2014-07-16 2020-06-10 Arrowhead Pharmaceuticals, Inc. Irna-zusammensetzungen zur behandlung von apoc3-bedingten erkrankungen
KR102689262B1 (ko) 2014-09-05 2024-07-30 피오 파마슈티칼스 코프. Tyr 또는 mmp1을 표적화하는 핵산을 사용한 노화 및 피부 장애의 치료 방법
EP3191592A1 (de) 2014-09-11 2017-07-19 Novartis AG Hemmung von prmt5 zur behandlung von erkrankungen im zusammenhang mit mtap-mangel
WO2016089883A1 (en) 2014-12-01 2016-06-09 Novartis Ag Compositions and methods for diagnosis and treatment of prostate cancer
US9976141B2 (en) * 2015-05-29 2018-05-22 Arrowhead Pharmaceuticals, Inc. Compositions and methods for inhibiting gene expression of Hif2alpha
WO2016196366A1 (en) 2015-05-29 2016-12-08 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Extension of replicative lifespan in diseases of premature aging using p53 isoforms
WO2016193945A2 (en) 2015-06-05 2016-12-08 Novartis Ag Methods and compositions for diagnosing, treating, and monitoring treatment of shank3 deficiency associated disorders
CN108135923B (zh) 2015-07-06 2021-03-02 菲奥医药公司 靶向超氧化物歧化酶1（sod1）的核酸分子
WO2017007825A1 (en) 2015-07-06 2017-01-12 Rxi Pharmaceuticals Corporation Methods for treating neurological disorders using a synergistic small molecule and nucleic acids therapeutic approach
EP3365446A4 (de) 2015-10-19 2019-06-26 Phio Pharmaceuticals Corp. Gegen lange nichtcodierende rna gerichtete kleine selbstfreisetzende nukleinsäureverbindungen
CA3033867A1 (en) 2016-08-17 2018-02-22 Solstice Biologics, Ltd. Polynucleotide constructs
WO2018047148A1 (en) 2016-09-12 2018-03-15 Novartis Ag Compounds for the inhibition of mirna
EP3645546A4 (de) 2017-06-30 2021-12-01 Solstice Biologics, Ltd. Chirale phosphoramidithilfsmittel und verfahren zu ihrer verwendung
US11530413B2 (en) 2017-07-21 2022-12-20 Novartis Ag Compositions and methods to treat cancer
CA3074303A1 (en) 2017-09-11 2019-03-14 Arrowhead Pharmaceuticals, Inc. Rnai agents and compositions for inhibiting expression of apolipoprotein c-iii (apoc3)
EP3788138A1 (de) 2018-05-02 2021-03-10 Novartis AG Regulatoren von menschlichen pluripotenten stammzellen und verwendungen davon
SG11202105577TA (en) 2019-01-09 2021-06-29 Arrowhead Pharmaceuticals Inc Rnai agents for inhibiting expression of hif-2 alpha (epas1), compositions thereof, and methods of use
GB2603454A (en) 2020-12-09 2022-08-10 Ucl Business Ltd Novel therapeutics for the treatment of neurodegenerative disorders
GB202117758D0 (en) 2021-12-09 2022-01-26 Ucl Business Ltd Therapeutics for the treatment of neurodegenerative disorders
CN121285640A (zh) 2023-06-16 2026-01-06 基因泰克公司 评估剪接转换aso特征的方法
WO2025072615A1 (en) 2023-09-29 2025-04-03 Orbital Therapeutics, Inc. Improved methods of making rna by splinted ligation and compositions thereof

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6113946A (en) * 1992-04-03 2000-09-05 The Regents Of The University Of California Self-assembling polynucleotide delivery system comprising dendrimer polycations
ES2211882T3 (es) * 1993-07-14 2004-07-16 The Regents Of The University Of California Sistema de cesion de polinucleotido, automontable que comprende policationes de dendrimeros.
AU785007B2 (en) * 1999-11-24 2006-08-24 Mcs Micro Carrier Systems Gmbh Polypeptides comprising multimers of nuclear localization signals or of protein transduction domains and their use for transferring molecules into cells
US6632616B2 (en) * 2000-03-16 2003-10-14 Duke University Compounds that selectively bind to expanded polyglutamine repeat domains and methods of use thereof
CA2417454A1 (en) * 2000-07-31 2002-02-07 Active Motif Peptide-mediated delivery of molecules into cells
GB0022101D0 (en) * 2000-09-08 2000-10-25 Phogen Ltd Delivery of substances to cells
AU2001290949A1 (en) * 2000-09-14 2002-03-26 California Pacific Medical Center Id-1 and id-2 genes and products as diagnostic and prognostic markers and therapeutic targets for treatment of breast cancer and other types of carcinoma
WO2002026867A2 (en) * 2000-09-29 2002-04-04 The Regents Of The University Of California Dendrimeric support or carrier macromolecule
IL155991A0 (en) * 2000-12-01 2003-12-23 Max Planck Gesellschaft Rna interference mediating small rna molecules
EP2128248B2 (de) * 2002-02-01 2017-01-11 Life Technologies Corporation Oligonukleotid-Zusammensetzungen mit verbesserter Wirksamkeit
US20060009409A1 (en) * 2002-02-01 2006-01-12 Woolf Tod M Double-stranded oligonucleotides

Also Published As

Publication number Publication date
EP1585756A4 (de) 2007-02-14
EP1585756A2 (de) 2005-10-19
ATE465255T1 (de) 2010-05-15
US20040204377A1 (en) 2004-10-14
AU2003298724A1 (en) 2004-06-18
WO2004048545A3 (en) 2005-04-21
ES2343318T3 (es) 2010-07-28
CA2506714A1 (en) 2004-06-10
EP1585756B1 (de) 2010-04-21
US20110086425A1 (en) 2011-04-14
WO2004048545A2 (en) 2004-06-10
AU2003298724B2 (en) 2009-12-24

Similar Documents

Publication Publication Date Title
ATE465255T1 (de) Verabreichung von sirnas
BRPI0507680A (pt) partìculas de fosfato de cálcio terapêuticas e métodos de fabricação e uso das mesmas
ATE368054T1 (de) Verbindungen und methoden zur modulierung von occludin-abhängiger gewebepermeabilität
NO20044039L (no) Konjugatorer av terapeutiske eller cytotoksiske midler og biologisk aktive peptider.
YU9404A (sh) Multimerna, usmerena kontrastna sredstva na bazi peptida
DE60237162D1 (de) Liposomenladung mit metallionen
CY1119243T1 (el) Φαρμακοτεχνικες μορφες ανταγωνιστη του vegf
EA200100939A1 (ru) Продолжительно действующие инсулинотропные пептиды
MY136095A (en) Use of human anti-ctla-4 antibodies for treatment of cancer
AU2003267581A8 (en) Drug delivery
BRPI0917535A8 (pt) uso de insulina de ação ultra rápida
TNSN03116A1 (en) Pulmonary administration of chemically modified insulin
ATE374625T1 (de) Dendrimere zur verwendung in gezielter verabreichung
HUP0200418A2 (hu) Új citokin zalpha 11 ligandum
ATE495739T1 (de) Pharmazeutische zusammensetzungen und verfahren zur verwendung von levodopa und carbidopa
WO2006015258A3 (en) Methods and compositions related to argonaute proteins
MX337358B (es) Conjugados de disorazoles y sus derivados con moleculas de union con celulas, nuevos derivados de disorazol, procesos de fabricacion y usos de los mismos.
AU302605S (en) Aquarium
ATE363072T1 (de) Monoklonaler antikörper gegen mxa und mxb
BRPI0812026A2 (pt) mutantes de vegf-d e seu uso
AU301524S (en) Speaker
AU304748S (en) Laser level
UY26127A1 (es) Antígeno asociado con tumores
AU301726S (en) Necklace
AU310692S (en) Cup

Legal Events

Date Code Title Description
8364 No opposition during term of opposition